STOCK TITAN
  1. Home
  2. Sec-filings
  3. KA
  4. [Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Kineta Board Member's Stock Moves Signal Confidence During TuHURA Merger

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kineta Director Kimberlee C. Drapkin reported multiple securities transactions on Form 4, detailing changes in beneficial ownership on June 23-25, 2025:

  • Exercised 12,500 stock options at $0.611 per share on June 23
  • Disposed of 4,706 common shares at $0.26 per share through tax withholding (Form F)
  • Received 6,000 new shares as an award on June 25 at $0 cost

The transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. Per the Optionholder Treatment Agreement dated June 16, 2025, and merger agreement dated December 11, 2024 (amended May 5, 2025), the reporting person's options under the 2022 Equity Incentive Plan became fully vested. Following all transactions, Drapkin directly owns 13,794 common shares with no remaining stock options.

Positive

  • Director received 6,000 shares as new stock grant, demonstrating continued alignment with shareholder interests

Negative

  • None.
Insider Drapkin Kimberlee C
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 6,000 $0.00 --
Exercise Stock Option (Right to Buy) 12,500 $0.00 --
Exercise Common Stock 12,500 $0.611 $8K
Tax Withholding Common Stock 4,706 $0.26 $1K
Holdings After Transaction: Common Stock — 13,794 shares (Direct); Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Drapkin Kimberlee C
(Last) (First) (Middle)
C/O KINETA, INC.
7683 SE 27TH STREET, SUITE 481
(Street)
MERCER ISLAND WA 98040
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/23/2025 M 12,500 A $0.611 12,500 D
Common Stock 06/23/2025 F 4,706 D $0.26 7,794 D
Common Stock 06/25/2025 A 6,000 A $0 13,794 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.611 06/23/2025 M 12,500 (1) 09/03/2034 Common Stock 12,500 $0 0 D
Explanation of Responses:
1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.
/s/ Nanette Agustines, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Kimberlee Drapkin make in KA stock on June 23, 2025?

On June 23, 2025, Kimberlee Drapkin exercised 12,500 stock options at $0.611 per share (acquired) and subsequently had 4,706 shares withheld for taxes (disposed) at $0.26 per share. After these transactions, she held 7,794 shares directly.

How many shares of KA stock did Kimberlee Drapkin receive as a grant on June 25, 2025?

Kimberlee Drapkin received a grant of 6,000 shares of KA common stock on June 25, 2025 at $0 cost, bringing her total direct holdings to 13,794 shares.

What was the exercise price of KA stock options that Drapkin exercised?

Kimberlee Drapkin exercised stock options with an exercise price of $0.611 per share. These options were originally set to expire on September 3, 2034, but were exercised early on June 23, 2025.

Why did KA director Kimberlee Drapkin's stock options vest early?

The options vested early on June 23, 2025, pursuant to an Optionholder Treatment Agreement dated June 16, 2025, and a merger agreement between Kineta and TuHURA Biosciences. This early vesting was approved by stockholders at a Special Meeting held on June 23, 2025.